Integrative analysis of expression profile indicates the ECM receptor and LTP dysfunction in the glioma-related

Zhi-Bin Wang1,2, Jian Qu3, Pan Xie1,2

  • 1Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, and National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008, P. R. China.

BMC Genomics
|June 8, 2022
PubMed
Abstract

Insights

This study reveals key microRNA, mRNA, and lncRNA changes in glioma-related epilepsy (GRE), offering new insights into brain network alterations and potential therapeutic targets for epilepsy in glioma patients.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Genomics

Background:

  • Seizures are a frequent complication in glioma patients, leading to neurological dysfunction.
  • The precise mechanisms underlying brain network alterations in glioma-related epilepsy (GRE) remain unclear.

Purpose of the Study:

  • To elucidate the pathogenic mechanisms of GRE by analyzing dynamic microRNA, mRNA, and lncRNA expression profiles.
  • To identify potential molecular targets for understanding and treating GRE.

Main Methods:

  • Comparative analysis of brain tissue from 16 GRE patients and 9 glioma without epilepsy (GNE) patients.
  • High-throughput microarray analysis of miRNA, lncRNA, and mRNA expression.
  • Bioinformatic analysis using R and Bioconductor to identify differentially expressed molecules and pathways.

Main Results:

  • Identified 3 differentially expressed miRNAs, 6 lncRNAs, and 49 mRNAs critical in GRE development.
  • Validated elevated expression of GABARAPL1, GRAMD1B, and IQSEC3 in the GRE group.
  • Constructed a significant lncRNA-microRNA-Gene regulatory network and implicated ECM receptor interaction and long-term potentiation pathways.

Conclusions:

  • The study provides a comprehensive molecular profile of GRE.
  • Findings offer novel perspectives on GRE-induced brain network changes and identify potential therapeutic avenues.